SLC5A2 and type 2 diabetes mellitus: Recently clinical studies conducted with SGLT2 inhibitors in subjects with T2D have demonstrated the ability of this class of drugs to achieve benefits at the cardiac and renal level due to their capacity to reduce the risk of hospitalizations for heart failure and the progression of the renal damage.